Insider Selling: Vericel Corp (NASDAQ:VCEL) CFO Sells $334,560.00 in Stock
Vericel Corp (NASDAQ:VCEL) CFO Gerard J. Michel sold 17,000 shares of the business’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $19.68, for a total transaction of $334,560.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
NASDAQ VCEL opened at $18.73 on Friday. The company has a current ratio of 8.47, a quick ratio of 8.16 and a debt-to-equity ratio of 0.24. The firm has a market capitalization of $822.45 million, a price-to-earnings ratio of -133.79 and a beta of 2.83. Vericel Corp has a one year low of $9.70 and a one year high of $21.00. The company has a fifty day simple moving average of $17.78.
Vericel (NASDAQ:VCEL) last posted its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.07) EPS for the quarter, meeting analysts’ consensus estimates of ($0.07). The company had revenue of $21.81 million for the quarter, compared to analyst estimates of $22.51 million. Vericel had a negative net margin of 3.51% and a negative return on equity of 3.40%. Vericel’s quarterly revenue was up 21.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.21) earnings per share. Research analysts anticipate that Vericel Corp will post 0.09 EPS for the current year.
A number of research analysts have commented on VCEL shares. Oppenheimer dropped their price objective on shares of 2U from $83.00 to $67.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 8th. BidaskClub upgraded shares of Xilinx from a “hold” rating to a “buy” rating in a research note on Saturday, June 29th. Finally, Zacks Investment Research lowered shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $22.98.
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.
Further Reading: What is a Roth IRA?
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.